Jasmin Hundal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jasmin Hundal has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Naga Vaishnavi Gadela
Internal Medicine, University of Connecticut, Farmington, USA
2 shared publications - Nerea Lopetegui-Lia
Internal Medicine, University of Connecticut Health Center, Farmington, USA
2 shared publications Abhinav Anand Vayal Veettil
Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH
1 shared publication- Abhishek Jaiswal
Hartford Healthcare Heart and Vascular Institute, Hartford Hospital, Hartford, CT
1 shared publication Aditi Singh
Department of Internal Medicine, University of Connecticut, Farmington, CT, USA
1 shared publication- Alexander R. Vartanov
Internal Medicine, University of Connecticut, Farmington, USA
1 shared publication
Latest Publications
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600061
Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications
Breast cancer is increasingly recognized as an obesity-associated disease, with obesity linked to higher risk of postmenopausal estrogen receptor–positive disease and adverse outcomes across stages. Adipose tissue dysfunction in chronic energy excess drives a tumor-supportive milieu: Crown-like structures and macrophage inflammation increase local aromatase and estrogen production, while elevated free fatty acids contribute to hyperinsulinemia and IGF-1 signaling with activation of PI3K/Akt/mTOR and MAPK pathways; leptin is increased and adiponectin reduced, amplifying proliferative and inflammatory cues. Standard breast cancer therapies can further worsen weight gain and insulin resistance, increasing symptom burden, reducing quality of life, and potentially compromising treatment delivery. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective agents for obesity and type 2 diabetes that improve glycemic control and reduce cardiovascular risk, prompting growing use in patients with breast cancer. Available breast cancer–specific data are largely retrospective and suggest clinically meaningful but attenuated weight loss compared with pivotal obesity trials, with concurrent aromatase inhibitor or tamoxifen use associated with smaller reductions. No unique breast cancer toxicities have been identified to date, to our knowledge, but clinicians should monitor GI tolerability, hydration and nutrition, and changes in body composition, including potential lean mass loss that may be mitigated with resistance training and adequate protein intake. Clinical considerations include changes in breast imaging during rapid weight loss (including possible increases in mammographic density), uncertainty regarding perioperative use in reconstructive surgery, and careful attribution of GI symptoms to GLP-1RA therapy versus chemotherapy. Studies also suggest potential survivorship benefits relevant to lymphedema and cardio-oncology, although causality is unproven. Prospective cancer-specific trials and implementation studies are needed to define safety; optimal timing; patient selection; and effects on oncologic outcomes, function, and quality of life.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600061
Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications
Breast cancer is increasingly recognized as an obesity-associated disease, with obesity linked to higher risk of postmenopausal estrogen receptor–positive disease and adverse outcomes across stages. Adipose tissue dysfunction in chronic energy excess drives a tumor-supportive milieu: Crown-like structures and macrophage inflammation increase local aromatase and estrogen production, while elevated free fatty acids contribute to hyperinsulinemia and IGF-1 signaling with activation of PI3K/Akt/mTOR and MAPK pathways; leptin is increased and adiponectin reduced, amplifying proliferative and inflammatory cues. Standard breast cancer therapies can further worsen weight gain and insulin resistance, increasing symptom burden, reducing quality of life, and potentially compromising treatment delivery. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective agents for obesity and type 2 diabetes that improve glycemic control and reduce cardiovascular risk, prompting growing use in patients with breast cancer. Available breast cancer–specific data are largely retrospective and suggest clinically meaningful but attenuated weight loss compared with pivotal obesity trials, with concurrent aromatase inhibitor or tamoxifen use associated with smaller reductions. No unique breast cancer toxicities have been identified to date, to our knowledge, but clinicians should monitor GI tolerability, hydration and nutrition, and changes in body composition, including potential lean mass loss that may be mitigated with resistance training and adequate protein intake. Clinical considerations include changes in breast imaging during rapid weight loss (including possible increases in mammographic density), uncertainty regarding perioperative use in reconstructive surgery, and careful attribution of GI symptoms to GLP-1RA therapy versus chemotherapy. Studies also suggest potential survivorship benefits relevant to lymphedema and cardio-oncology, although causality is unproven. Prospective cancer-specific trials and implementation studies are needed to define safety; optimal timing; patient selection; and effects on oncologic outcomes, function, and quality of life.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 46 (3) , e517280
Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation
Artificial intelligence (AI) is increasingly integrated into oncology across clinical care, research workflows, and translational implementation. This chapter provides a practical overview of these domains, emphasizing opportunities and limitations relevant to real-world oncology practice. In clinical care, AI applications include ambient documentation systems, decision support tools, and remote monitoring platforms. These technologies may reduce administrative burden, assist with evidence synthesis and guideline navigation, and enable longitudinal assessment of symptoms and functional status through wearable and patient-reported data. Emerging tools such as large language models also support patient communication through education, translation, and symptom triage. However, across these applications, performance remains dependent on data quality, validation, and appropriate clinical oversight. In research and scholarship, AI is increasingly used to support grant development, study design, literature review, and manuscript preparation. These tools may improve efficiency, enhance clarity, and assist in identifying research gaps or methodological approaches. At the same time, concerns regarding accuracy, hallucinated content, data privacy, and ethical responsibility require careful oversight. The responsibility for hypothesis generation, methodological rigor, and scientific integrity remains with the investigator. From a translational perspective, a persistent gap exists between model development and clinical deployment. Differences in data quality, infrastructure, and patient populations may limit generalizability, while workflow integration, clinician readiness, and bias mitigation remain critical challenges. Collectively, AI has the potential to enhance oncology care and research, but its impact depends on rigorous validation, equitable implementation, and sustained human oversight.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 46 (3) , e517280
Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation
Artificial intelligence (AI) is increasingly integrated into oncology across clinical care, research workflows, and translational implementation. This chapter provides a practical overview of these domains, emphasizing opportunities and limitations relevant to real-world oncology practice. In clinical care, AI applications include ambient documentation systems, decision support tools, and remote monitoring platforms. These technologies may reduce administrative burden, assist with evidence synthesis and guideline navigation, and enable longitudinal assessment of symptoms and functional status through wearable and patient-reported data. Emerging tools such as large language models also support patient communication through education, translation, and symptom triage. However, across these applications, performance remains dependent on data quality, validation, and appropriate clinical oversight. In research and scholarship, AI is increasingly used to support grant development, study design, literature review, and manuscript preparation. These tools may improve efficiency, enhance clarity, and assist in identifying research gaps or methodological approaches. At the same time, concerns regarding accuracy, hallucinated content, data privacy, and ethical responsibility require careful oversight. The responsibility for hypothesis generation, methodological rigor, and scientific integrity remains with the investigator. From a translational perspective, a persistent gap exists between model development and clinical deployment. Differences in data quality, infrastructure, and patient populations may limit generalizability, while workflow integration, clinician readiness, and bias mitigation remain critical challenges. Collectively, AI has the potential to enhance oncology care and research, but its impact depends on rigorous validation, equitable implementation, and sustained human oversight.
- 29 September 2025
- Published by SAGE Publications in AI in Precision Oncology
- Vol. 2 (5) , 158-162
Ambient Artificial Intelligence in Health Care Documentation: A Review of Tools, Integration, and Clinical Implications
Introduction: Ambient artificial intelligence (AAI) is increasingly being integrated into clinical workflows to address the documentation burden contributing to clinician burnout. AAI systems use automatic speech recognition and natural language processing to capture real-time clinician–patient dialogue and generate structured documentation within the electronic health record. Methods: This review examines AAI’s technical foundations, clinical applications, and implementation considerations in oncology practice. We describe how current AAI tools extract, classify, and populate relevant clinical content, such as the history of present illness, physical examination findings, and assessment and plan, while adhering to established US coding standards (e.g., International Classification of Diseases [ICD-10]). Key commercially available systems, including Nuance DAX Copilot, Ambience Healthcare, Tali AI, Athelas Scribe, and Nabla, are compared in terms of functionality, integration capabilities, and reported outcomes. Practical guidance is provided on clinician onboarding, device setup, customization, and patient consent. Results: Early data suggest AAI implementation can reduce after-hours documentation, improve note quality, and enhance coding accuracy. However, barriers such as transcription errors, hallucinations, and workflow disruptions must be proactively addressed. To ensure safe and effective integration, oncology practices adopting AAI should prioritize targeted training, documentation oversight, and user feedback. Conclusion: Although preliminary findings are promising, further prospective, multi-institutional studies are warranted to evaluate the impact of AAI on clinical efficiency, data quality, and patient outcomes in oncology. This review provides a foundational framework for researchers, clinicians, and health systems seeking to implement AAI in precision oncology documentation.
- 29 September 2025
- Published by SAGE Publications in AI in Precision Oncology
- Vol. 2 (5) , 158-162
Ambient Artificial Intelligence in Health Care Documentation: A Review of Tools, Integration, and Clinical Implications
Introduction: Ambient artificial intelligence (AAI) is increasingly being integrated into clinical workflows to address the documentation burden contributing to clinician burnout. AAI systems use automatic speech recognition and natural language processing to capture real-time clinician–patient dialogue and generate structured documentation within the electronic health record. Methods: This review examines AAI’s technical foundations, clinical applications, and implementation considerations in oncology practice. We describe how current AAI tools extract, classify, and populate relevant clinical content, such as the history of present illness, physical examination findings, and assessment and plan, while adhering to established US coding standards (e.g., International Classification of Diseases [ICD-10]). Key commercially available systems, including Nuance DAX Copilot, Ambience Healthcare, Tali AI, Athelas Scribe, and Nabla, are compared in terms of functionality, integration capabilities, and reported outcomes. Practical guidance is provided on clinician onboarding, device setup, customization, and patient consent. Results: Early data suggest AAI implementation can reduce after-hours documentation, improve note quality, and enhance coding accuracy. However, barriers such as transcription errors, hallucinations, and workflow disruptions must be proactively addressed. To ensure safe and effective integration, oncology practices adopting AAI should prioritize targeted training, documentation oversight, and user feedback. Conclusion: Although preliminary findings are promising, further prospective, multi-institutional studies are warranted to evaluate the impact of AAI on clinical efficiency, data quality, and patient outcomes in oncology. This review provides a foundational framework for researchers, clinicians, and health systems seeking to implement AAI in precision oncology documentation.
- 12 July 2025
- Published by SAGE Publications in American Journal of Lifestyle Medicine
Implementing Lifestyle Medicine in Cancer Survivorship: A Narrative Review of Global Models
Cardiovascular disease and cancer are the leading causes of mortality in developed countries. Advances in screening and treatment have led to a growing population of cancer survivors who require long-term supportive care. Many experience persistent health challenges, including fatigue, functional decline, and cardiometabolic comorbidities. Lifestyle medicine, which includes nutrition, physical activity, stress management, sleep, social connections, and risk reduction, provides a structured approach to optimizing survivorship outcomes.This narrative review examines the role of Lifestyle Medicine in oncology and highlights global implementation models. Programs analyzed include the Mass General Cancer Center’s Lifestyle Medicine Clinic, the Clinical Oncology Society of Australia’s exercise oncology framework, the Cleveland Clinic Abu Dhabi’s Lifestyle Medicine Oncology Program, and Kansas City’s community-based Cancer Wellness for Life initiative. Across diverse clinical settings, structured lifestyle interventions have been associated with improved treatment tolerance, quality of life, and the potential to reduce cardiometabolic risk factors. Hospital-based programs integrate multidisciplinary support, while community-driven initiatives expand access to lifestyle interventions. Despite strong evidence supporting these approaches, barriers to widespread adoption include gaps in clinician training, limited institutional support, and disparities in patient access. Global models show the feasibility and advantages of integrating Lifestyle Medicine into survivorship care. Increasing access, overcoming implementation challenges, and using technology can improve survivorship outcomes. Including Lifestyle Medicine in standard oncology care can improve long-term health and encourage survivors to manage their well-being actively.
- 12 July 2025
- Published by SAGE Publications in American Journal of Lifestyle Medicine
Implementing Lifestyle Medicine in Cancer Survivorship: A Narrative Review of Global Models
Cardiovascular disease and cancer are the leading causes of mortality in developed countries. Advances in screening and treatment have led to a growing population of cancer survivors who require long-term supportive care. Many experience persistent health challenges, including fatigue, functional decline, and cardiometabolic comorbidities. Lifestyle medicine, which includes nutrition, physical activity, stress management, sleep, social connections, and risk reduction, provides a structured approach to optimizing survivorship outcomes.This narrative review examines the role of Lifestyle Medicine in oncology and highlights global implementation models. Programs analyzed include the Mass General Cancer Center’s Lifestyle Medicine Clinic, the Clinical Oncology Society of Australia’s exercise oncology framework, the Cleveland Clinic Abu Dhabi’s Lifestyle Medicine Oncology Program, and Kansas City’s community-based Cancer Wellness for Life initiative. Across diverse clinical settings, structured lifestyle interventions have been associated with improved treatment tolerance, quality of life, and the potential to reduce cardiometabolic risk factors. Hospital-based programs integrate multidisciplinary support, while community-driven initiatives expand access to lifestyle interventions. Despite strong evidence supporting these approaches, barriers to widespread adoption include gaps in clinician training, limited institutional support, and disparities in patient access. Global models show the feasibility and advantages of integrating Lifestyle Medicine into survivorship care. Increasing access, overcoming implementation challenges, and using technology can improve survivorship outcomes. Including Lifestyle Medicine in standard oncology care can improve long-term health and encourage survivors to manage their well-being actively.
- 1 December 2022
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (4) , 992-995
Safe administration of temozolomide in end-stage renal disease patients
Introduction: Glioblastoma multiforme is the most common and aggressive type of central nervous system tumor. We present a novel case of the challenges of dosing temozolomide in a patient with end stage renal disease on peritoneal hemodialysis with unpredictable clearance and toxicities. Case report: In this case, a 60-year-old male with a past medical history of hypertension and Stage V chronic kidney disease presented with worsening confusion and word-finding difficulty in the emergency department. Magnetic resonance imaging demonstrated a large intra-axial mass within the posterior left frontal lobe measuring 4.5 × 4.1 × 3.5 cm with irregularly, predominant peripheral tumoral enhancement. Management and outcome: The patient underwent a surgical resection which confirmed the diagnosis of glioblastoma (grade 4). The standard treatment for glioblastoma is 6 weeks of radiation therapy and daily temozolomide. Given his history of renal dysfunction and limited data on the safety of temozolomide in patients on hemodialysis (HD), the patient was administered dose-reduced temozolomide and closely monitored for toxicities. Temozolomide was successfully up-titrated to the full dose. Discussion: Renal replacement therapy is a life-saving treatment for end-stage kidney disease patients. A stepwise increase in the dosage of temozolomide did not increase the risk of toxicity with HD. There are no studies with patients on temozolomide and peritoneal dialysis. Our case transitioned to peritoneal dialysis from HD without significant toxicity from temozolomide. As a more substantial proportion of the population becomes dialysis-dependent in the coming years, we need further studies to understand the safety profiles of chemotherapeutic agents in this complex subset of patients.
- 1 December 2022
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (4) , 992-995
Safe administration of temozolomide in end-stage renal disease patients
Introduction: Glioblastoma multiforme is the most common and aggressive type of central nervous system tumor. We present a novel case of the challenges of dosing temozolomide in a patient with end stage renal disease on peritoneal hemodialysis with unpredictable clearance and toxicities. Case report: In this case, a 60-year-old male with a past medical history of hypertension and Stage V chronic kidney disease presented with worsening confusion and word-finding difficulty in the emergency department. Magnetic resonance imaging demonstrated a large intra-axial mass within the posterior left frontal lobe measuring 4.5 × 4.1 × 3.5 cm with irregularly, predominant peripheral tumoral enhancement. Management and outcome: The patient underwent a surgical resection which confirmed the diagnosis of glioblastoma (grade 4). The standard treatment for glioblastoma is 6 weeks of radiation therapy and daily temozolomide. Given his history of renal dysfunction and limited data on the safety of temozolomide in patients on hemodialysis (HD), the patient was administered dose-reduced temozolomide and closely monitored for toxicities. Temozolomide was successfully up-titrated to the full dose. Discussion: Renal replacement therapy is a life-saving treatment for end-stage kidney disease patients. A stepwise increase in the dosage of temozolomide did not increase the risk of toxicity with HD. There are no studies with patients on temozolomide and peritoneal dialysis. Our case transitioned to peritoneal dialysis from HD without significant toxicity from temozolomide. As a more substantial proportion of the population becomes dialysis-dependent in the coming years, we need further studies to understand the safety profiles of chemotherapeutic agents in this complex subset of patients.
- 1 December 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (12) , e1987-e1995
Defining the Current Landscape, Attitudes, and Perceived Barriers of Virtual Medicine in Underserved Populations
PURPOSE: Virtual medicine (VM) use increased during the COVID-19 pandemic as it represented a safe alternative to traditional face-to-face health care delivery. This prospective cross-sectional study aimed to characterize preferences and perceived barriers to VM on the basis of language and specific sociodemographic variables while also identifying particular subpopulations at risk of dissatisfaction regarding VM. METHODS: An institutional review board–approved, 23-item questionnaire was offered in English and Spanish. Examined variables included demographic information, preferences, and perceived barriers regarding VM. Multivariable analysis was performed to determine the association between demographic variables and participants' preferences and perceived barriers. RESULTS: Fewer Hispanic and underserved patients (N = 241) had received oncological care through VM (28.9% v 30.8%) despite comparable preferences and levels of satisfaction regarding the incorporation of VM in health care delivery (21.6% v 25.4%; 68.7% v 82.1%), respectively, with no significant difference by age, level of education, marital status, or Hispanic ethnicity, although Spanish as primary language was statistically significant ( P = .001). Although Hispanic and underserved rely more on social media to receive health information (26.5% v 24.7%), they have more technical barriers. They were up to 2.9 times more likely not to have a phone/iPad/similar or access broadband connectivity. CONCLUSION: Given the shift toward outpatient and home-based care, an aging population, and cultural appropriations, VM excitedly allows the reincorporation of family/caregiver in medical engagement. Hispanic patients are equally interested and satisfied in receiving oncological care through VM, but fewer are currently using it. Barriers are predominantly technical and targetable with appropriate policies to help overcome technological barriers on the basis of language, ethnic, locoregional, and sociodemographic variables.
- 1 December 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (12) , e1987-e1995
Defining the Current Landscape, Attitudes, and Perceived Barriers of Virtual Medicine in Underserved Populations
PURPOSE: Virtual medicine (VM) use increased during the COVID-19 pandemic as it represented a safe alternative to traditional face-to-face health care delivery. This prospective cross-sectional study aimed to characterize preferences and perceived barriers to VM on the basis of language and specific sociodemographic variables while also identifying particular subpopulations at risk of dissatisfaction regarding VM. METHODS: An institutional review board–approved, 23-item questionnaire was offered in English and Spanish. Examined variables included demographic information, preferences, and perceived barriers regarding VM. Multivariable analysis was performed to determine the association between demographic variables and participants' preferences and perceived barriers. RESULTS: Fewer Hispanic and underserved patients (N = 241) had received oncological care through VM (28.9% v 30.8%) despite comparable preferences and levels of satisfaction regarding the incorporation of VM in health care delivery (21.6% v 25.4%; 68.7% v 82.1%), respectively, with no significant difference by age, level of education, marital status, or Hispanic ethnicity, although Spanish as primary language was statistically significant ( P = .001). Although Hispanic and underserved rely more on social media to receive health information (26.5% v 24.7%), they have more technical barriers. They were up to 2.9 times more likely not to have a phone/iPad/similar or access broadband connectivity. CONCLUSION: Given the shift toward outpatient and home-based care, an aging population, and cultural appropriations, VM excitedly allows the reincorporation of family/caregiver in medical engagement. Hispanic patients are equally interested and satisfied in receiving oncological care through VM, but fewer are currently using it. Barriers are predominantly technical and targetable with appropriate policies to help overcome technological barriers on the basis of language, ethnic, locoregional, and sociodemographic variables.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 231
Sociodemographic and occupational factors associated with receipt of work accommodations among employed breast cancer survivors.
231 Background: Many cancer survivors face occupational challenges when staying in or returning to work after treatment yet little is known about sociodemographic and work-related factors associated with receipt of work accommodations (e.g. flexible work time, reduced workload). Methods: We analyzed data from the PinkWorks study (n = 154 female breast cancer survivors), a cross-sectional online survey. Participants were: ≥18+ years, speak English, ended treatment within 36 months, and working ≥20 hours per week at both the time of diagnosis and currently. Due to small n’s in strata, we performed descriptive analyses (frequencies, Chi-Square tests) to identify possible univariate associations between occupational factors and granting of work accommodations. An exploratory multiple Logistic Regression was performed with receipt of accommodations (yes, no) as the dependent variable. Results: Among participants, 43.8% received work accommodations from employers, and 11% reported that their physicians had a direct conversation with their employer. Participants who were native English speakers were more likely to receive work accommodations compared to those where English is a second language (44.8%, 22.2%, respectively, n.s.). Workers who held executive positions were more likely to receive accommodations compared to those in either supervisory or non-supervisory roles (60.0%, 43.1%, 42.9%, respectively, n.s.). We observed a higher prevalence of work accommodations among participants who reported that a discussion between the physician and employer occurred compared to those who did not report such a conversation (58%, 41.9%, respectively, n.s.) An exploratory logistic regression controlling for age and educational attainment was consistent with descriptive findings regarding language and type of position. Conclusions: Less than half of employed breast cancer survivors were provided work accommodations. Suggestive disparities in the receipt of accommodations were observed among those who were not native English speakers or in non-executive positions. The occurrence of a conversation between the participant’s physician and employer was linked to a higher prevalence of accommodations but the cross-sectional design of the study limits interpretation. Additional multivariate analyses are recommended to further explore these relationships, including structural equation modeling to address the strong interconnections among the study variables.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 231
Sociodemographic and occupational factors associated with receipt of work accommodations among employed breast cancer survivors.
231 Background: Many cancer survivors face occupational challenges when staying in or returning to work after treatment yet little is known about sociodemographic and work-related factors associated with receipt of work accommodations (e.g. flexible work time, reduced workload). Methods: We analyzed data from the PinkWorks study (n = 154 female breast cancer survivors), a cross-sectional online survey. Participants were: ≥18+ years, speak English, ended treatment within 36 months, and working ≥20 hours per week at both the time of diagnosis and currently. Due to small n’s in strata, we performed descriptive analyses (frequencies, Chi-Square tests) to identify possible univariate associations between occupational factors and granting of work accommodations. An exploratory multiple Logistic Regression was performed with receipt of accommodations (yes, no) as the dependent variable. Results: Among participants, 43.8% received work accommodations from employers, and 11% reported that their physicians had a direct conversation with their employer. Participants who were native English speakers were more likely to receive work accommodations compared to those where English is a second language (44.8%, 22.2%, respectively, n.s.). Workers who held executive positions were more likely to receive accommodations compared to those in either supervisory or non-supervisory roles (60.0%, 43.1%, 42.9%, respectively, n.s.). We observed a higher prevalence of work accommodations among participants who reported that a discussion between the physician and employer occurred compared to those who did not report such a conversation (58%, 41.9%, respectively, n.s.) An exploratory logistic regression controlling for age and educational attainment was consistent with descriptive findings regarding language and type of position. Conclusions: Less than half of employed breast cancer survivors were provided work accommodations. Suggestive disparities in the receipt of accommodations were observed among those who were not native English speakers or in non-executive positions. The occurrence of a conversation between the participant’s physician and employer was linked to a higher prevalence of accommodations but the cross-sectional design of the study limits interpretation. Additional multivariate analyses are recommended to further explore these relationships, including structural equation modeling to address the strong interconnections among the study variables.
- Open Access
- 30 July 2022
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 26 (8) , 970-973
Rare Case of Refractory Hypoxia and Severe Multiorgan Failure from Secondary Lymphohistiocytosis Successfully Bridged to Treatment with Extracorporeal Membrane Oxygenation Support
Introduction: Acute respiratory distress syndrome (ARDS) is an uncommon complication of hemophagocytic lymphohistiocytosis (HLH). Non-specific findings that mimic other diseases make timely diagnosis and treatment challenging. We present a rare case of severe ARDS and multiorgan failure from secondary HLH due to peripheral T-cell lymphoma. Case presentation: A middle-aged female presented with dry cough and fever for three days. On presentation, the patient was febrile to 105 degrees F and hypoxic to 88% on room air. Chest X-ray showed bilateral interstitial infiltrates. Laboratory investigations showed lymphopenia and elevated inflammatory markers. The viral panel, including coronavirus disease-2019 (COVID-19), influenza, and respiratory syncytial virus (RSV), was negative. Her respiratory status progressively worsened, requiring invasive mechanical ventilation for ARDS. Despite lung-protective ventilation, prone positioning, and the use of paralytic agents, the patient continued to remain hypoxic, necessitating extracorporeal membrane oxygenation (ECMO) support.The patient was started on antibiotics and high-dose steroid.Thereafter, she developed a leukemoid reaction, and the ferritin level started rising; raising suspicion for lymphophagocytosis. During this time, she also developed acute liver and kidney failure and required multiple vasopressors and renal replacement therapy. Eventually, a diagnosis of mature peripheral T-cell lymphoma was established. Subsequently, her respiratory status and multiorgan failure significantly improved, and ECMO was explanted after 2 weeks. She was started on etoposide and steroid, and eventually discharged after 6 weeks. Discussion: This is the first case describing a successful implementation of ECMO in an adult diagnosed with ARDS secondary to mature peripheral T-cell lymphoma; allowing for recovery of respiratory status, which was compromised during the initial cytokine storm and provided time to establish the diagnosis and initiate appropriate treatment of secondary HLH mature due to peripheral T-cell lymphoma, and in the end, prevented a fatality. We believe that ECMO may be appropriately instituted in rapidly deteriorating patients with an unknown illness refractory to conventional therapy, to allow for end-organ recovery, to reach a diagnosis, and to administer appropriate therapy.
- 30 July 2022
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 26 (8) , 970-973
Open AccessRare Case of Refractory Hypoxia and Severe Multiorgan Failure from Secondary Lymphohistiocytosis Successfully Bridged to Treatment with Extracorporeal Membrane Oxygenation Support
Introduction: Acute respiratory distress syndrome (ARDS) is an uncommon complication of hemophagocytic lymphohistiocytosis (HLH). Non-specific findings that mimic other diseases make timely diagnosis and treatment challenging. We present a rare case of severe ARDS and multiorgan failure from secondary HLH due to peripheral T-cell lymphoma. Case presentation: A middle-aged female presented with dry cough and fever for three days. On presentation, the patient was febrile to 105 degrees F and hypoxic to 88% on room air. Chest X-ray showed bilateral interstitial infiltrates. Laboratory investigations showed lymphopenia and elevated inflammatory markers. The viral panel, including coronavirus disease-2019 (COVID-19), influenza, and respiratory syncytial virus (RSV), was negative. Her respiratory status progressively worsened, requiring invasive mechanical ventilation for ARDS. Despite lung-protective ventilation, prone positioning, and the use of paralytic agents, the patient continued to remain hypoxic, necessitating extracorporeal membrane oxygenation (ECMO) support.The patient was started on antibiotics and high-dose steroid.Thereafter, she developed a leukemoid reaction, and the ferritin level started rising; raising suspicion for lymphophagocytosis. During this time, she also developed acute liver and kidney failure and required multiple vasopressors and renal replacement therapy. Eventually, a diagnosis of mature peripheral T-cell lymphoma was established. Subsequently, her respiratory status and multiorgan failure significantly improved, and ECMO was explanted after 2 weeks. She was started on etoposide and steroid, and eventually discharged after 6 weeks. Discussion: This is the first case describing a successful implementation of ECMO in an adult diagnosed with ARDS secondary to mature peripheral T-cell lymphoma; allowing for recovery of respiratory status, which was compromised during the initial cytokine storm and provided time to establish the diagnosis and initiate appropriate treatment of secondary HLH mature due to peripheral T-cell lymphoma, and in the end, prevented a fatality. We believe that ECMO may be appropriately instituted in rapidly deteriorating patients with an unknown illness refractory to conventional therapy, to allow for end-organ recovery, to reach a diagnosis, and to administer appropriate therapy.
- Open Access
- 13 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e25913
Discovery, Significance, and Utility of JAK2 Mutation in Squamous Cell Carcinoma of the Lung
Lung cancer continues to be the leading cause of cancer-related deaths worldwide. Many studies show lung cancer is a histologically and molecularly heterogeneous group, even within the same histological subtype. Liquid biopsies are a new tool that can identify targetable genomic mutations and impact management. JAK2 p.V617F is a mutation commonly found in myeloproliferative neoplasms but rarely identified in non-small cell lung cancer (NSCLCs). The significance of Janus Kinase (JAK2) mutation in lung cancer is not clearly understood. However, it is thought that it may have a role in treating solid tumors, such as lung cancer. We present two cases of patients diagnosed with NSCLC who were discovered to have JAK2 V617F mutation on liquid biopsy.
- 13 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e25913
Open AccessDiscovery, Significance, and Utility of JAK2 Mutation in Squamous Cell Carcinoma of the Lung
Lung cancer continues to be the leading cause of cancer-related deaths worldwide. Many studies show lung cancer is a histologically and molecularly heterogeneous group, even within the same histological subtype. Liquid biopsies are a new tool that can identify targetable genomic mutations and impact management. JAK2 p.V617F is a mutation commonly found in myeloproliferative neoplasms but rarely identified in non-small cell lung cancer (NSCLCs). The significance of Janus Kinase (JAK2) mutation in lung cancer is not clearly understood. However, it is thought that it may have a role in treating solid tumors, such as lung cancer. We present two cases of patients diagnosed with NSCLC who were discovered to have JAK2 V617F mutation on liquid biopsy.
- Open Access
- 25 February 2022
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e22635
Concurrent Lymphoma and COVID-19: Diagnostic and Therapeutic Challenges of High-Grade Lymphoma and COVID-19
The coronavirus disease 2019 (COVID-19) global pandemic has put an unprecedented strain on cancer care. The initial months were marred by fears of immunocompromised patients becoming opportunistic hosts to this deadly virus. We present a case of newly diagnosed high-grade B-cell lymphoma in a patient with COVID-19 and discuss the diagnostic and therapeutic challenges posed. A 76-year-old female presented with one month of progressive malaise, poor appetite, weight loss, and night sweats. A surveillance COVID-19 polymerase chain reaction (PCR) resulted positive. With strict isolation precautions, the daily focused physical examination masked several key findings including multifocal adenopathy. She developed hypoxic respiratory failure and progressive transaminitis and cytopenias. Image-guided, rather than excisional, biopsy revealed high-grade B-cell lymphoma. Superimposed COVID-19 infection presented multiple challenges, but she completed treatment and achieved remission. Suspicion for underlying malignancy was high. Institutional concerns included obtaining imaging studies and the gold standard excisional tissue biopsy while maintaining acceptable staff exposure. Fortunately, a lymph node core biopsy confirmed the histopathological diagnosis of high-grade B-cell lymphoma. The administration of chemoimmunotherapy (rituximab, cyclophosphamide, doxorubicin, dose-reduced vincristine, and prednisone (R-CHOP)) posed inherent risks, notably, worsening cytopenias and hepatotoxicity. The approach to treatment was further complicated as the interaction of high-grade lymphoma and COVID-19 remained unclear. Medical teams have faced delays executing formerly routine diagnostic studies and formulating timely and appropriate treatment strategies. Careful consideration of risks and benefits must be weighed. A multidisciplinary approach is crucial to successfully treat patients. The relationship between COVID-19 and cancer treatment is yet to be established, and large sample-size studies are required.
- 25 February 2022
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e22635
Open AccessConcurrent Lymphoma and COVID-19: Diagnostic and Therapeutic Challenges of High-Grade Lymphoma and COVID-19
The coronavirus disease 2019 (COVID-19) global pandemic has put an unprecedented strain on cancer care. The initial months were marred by fears of immunocompromised patients becoming opportunistic hosts to this deadly virus. We present a case of newly diagnosed high-grade B-cell lymphoma in a patient with COVID-19 and discuss the diagnostic and therapeutic challenges posed. A 76-year-old female presented with one month of progressive malaise, poor appetite, weight loss, and night sweats. A surveillance COVID-19 polymerase chain reaction (PCR) resulted positive. With strict isolation precautions, the daily focused physical examination masked several key findings including multifocal adenopathy. She developed hypoxic respiratory failure and progressive transaminitis and cytopenias. Image-guided, rather than excisional, biopsy revealed high-grade B-cell lymphoma. Superimposed COVID-19 infection presented multiple challenges, but she completed treatment and achieved remission. Suspicion for underlying malignancy was high. Institutional concerns included obtaining imaging studies and the gold standard excisional tissue biopsy while maintaining acceptable staff exposure. Fortunately, a lymph node core biopsy confirmed the histopathological diagnosis of high-grade B-cell lymphoma. The administration of chemoimmunotherapy (rituximab, cyclophosphamide, doxorubicin, dose-reduced vincristine, and prednisone (R-CHOP)) posed inherent risks, notably, worsening cytopenias and hepatotoxicity. The approach to treatment was further complicated as the interaction of high-grade lymphoma and COVID-19 remained unclear. Medical teams have faced delays executing formerly routine diagnostic studies and formulating timely and appropriate treatment strategies. Careful consideration of risks and benefits must be weighed. A multidisciplinary approach is crucial to successfully treat patients. The relationship between COVID-19 and cancer treatment is yet to be established, and large sample-size studies are required.